Eksjö County Hospital, Malmö, Sweden.
Cardiovasc Intervent Radiol. 2012 Oct;35(5):1009-15. doi: 10.1007/s00270-011-0229-4. Epub 2011 Jul 20.
This study was designed to assess aorto-iliac morphological characteristics in relation to reintervention and all-cause long-term mortality in patients undergoing standard EVAR for infrarenal AAA.
Patients treated with EVAR (Zenith(®) Stentgrafts, Cook) between May 1998 and February 2006 were prospectively enrolled in a computerized database where comorbidities and preoperative aneurysm morphology were entered. Reinterventions and mortality were checked until December 1, 2010. Median follow-up time was 68 months.
A total of 304 patients were included, of which 86% were men. Median age was 74 years. The reintervention rate was 23.4% (71/304). A greater diameter of the common iliac artery (p = 0.037; hazard ratio (HR) 1.037 [1.002-1.073]) was an independent factor for an increased number of reinterventions. The 30-day mortality rate was 3.0% (9/304). Aneurysm-related deaths due to AAA occurred in 4.9% (15/304). Five patients died due to a concomitant ruptured thoracic aortic aneurysm. The mortality until end of follow-up was 54.3% (165/304). The proportion of deaths caused by vascular diseases was 61.6%. The severity of angulation of the iliac arteries (p = 0.014; HR 1.018 [95% confidence interval (CI) 1.004-1.033]) and anemia (p = 0.044; HR 2.79 [95% CI 1.029-7.556]) remained as independent factors associated with all-cause long-term mortality. The crude reintervention-free survival rate at 1, 3, and 5 years was 84.5%, 64.8%, and 51.6%, respectively.
The initial aorto-iliac morphological state in patients scheduled for standard EVAR for AAA seems to be strongly related to the need for reinterventions and long-term mortality.
本研究旨在评估行标准腹主动脉瘤腔内修复术(EVAR)治疗肾下型AAA 患者的腹主动脉-髂动脉形态特征与再干预和全因长期死亡率之间的关系。
1998 年 5 月至 2006 年 2 月期间,前瞻性地将接受 EVAR(Zenith®Stentgrafts,Cook)治疗的患者纳入计算机数据库,其中记录了合并症和术前动脉瘤形态。直至 2010 年 12 月 1 日,检查再干预和死亡率。中位随访时间为 68 个月。
共纳入 304 例患者,其中 86%为男性,中位年龄为 74 岁。再干预率为 23.4%(71/304)。髂总动脉直径较大(p=0.037;风险比(HR)1.037[1.002-1.073])是再干预次数增加的独立因素。30 天死亡率为 3.0%(9/304)。AAA 相关的动脉瘤破裂死亡发生率为 4.9%(15/304)。5 例患者因同时发生的胸主动脉瘤破裂而死亡。随访结束时的总死亡率为 54.3%(165/304)。血管疾病导致的死亡比例为 61.6%。髂动脉成角严重程度(p=0.014;HR 1.018[95%置信区间(CI)1.004-1.033])和贫血(p=0.044;HR 2.79[95% CI 1.029-7.556])仍然是与全因长期死亡率相关的独立因素。1、3、5 年无再干预生存率分别为 84.5%、64.8%和 51.6%。
计划行标准 EVAR 治疗 AAA 的患者的初始腹主动脉-髂动脉形态状态似乎与再干预和长期死亡率密切相关。